Compliance Strategy for Small to Midsized Companies

February 22, 2013

 

Published for Pharmaceutical Compliance Monitor

On Feb. 20, 2013, Jim Hoover’s article, “Compliance Strategy for Small to Midsized Companies,” published in the online version of Pharmaceutical Compliance Monitor. In the article, Jim discusses the basic steps that small to mid-sized pharmaceutical companies should take when conducting an internal investigation. He instructs  companies to carefully consider the scope and limits of the investigation, who should conduct the investigation, how to protect the relevant privileges, and the possible outcomes of the investigation, prior to conducting the investigation. By fully considering these factors, Jim suggests that companies will be in a better position to correct any problems identified and determine whether or not self-disclosure is warranted. For the full article, please click here.  





Legal Disclaimer:
No representation is made that the quality of services to be performed is greater than the quality of legal services performed by other lawyers.

Featured Attorneys

send article

TESTIMONIALS

  • “Scott generously provided advice and assistance to our small startup. He was responsive to our needs and tolerant of adjustments we requested throughout the development of our operating agreement. We’re probably one of Scott’s smallest clients, but he offered our startup his full attention and consideration as if we were one of his largest. We’re grateful for his help.”

    -Sam Pugh

  • “I continue to be amazed by his ability to recall a small fact from earlier on and how to apply it to our benefit.”

    -Chambers 2012

  • "...He is very good.”

    -Chambers 2012

  • “Their knowledge of the industry and ability to work with borrower's counsel in a number of difficult situations has been invaluable. The firm is very knowledgeable and brings a wealth of experience across multiple practices and disciplines. This provides a strong one-stop shopping experience when working with the firm.”

    -Chambers 2012

  • "Very good."

    -Chambers 2012